
Cambrium is a next-generation chemical manufacturer specializing in designing and producing high-performance molecules called Supermolecules™. These molecules are created using AI-driven molecular design technology that optimizes for improved performance and seamless integration with existing industrial processes. Cambrium manufactures these novel molecules using biotechnology, enabling the creation of innovative materials that are better for people and the planet. Their business model focuses on partnering with companies to solve material challenges by delivering superior molecular solutions, with manufacturing capabilities that utilize local feedstocks close to customers. They have demonstrated successful projects including outperforming polyurethanes, creating PVC alternatives, and producing natural retinol replacements and hair bonding solutions. Cambrium is positioned as a resilient manufacturer leveraging synthetic biology, machine learning, and lab automation to accelerate biomaterial innovation at scale.

Cambrium is a next-generation chemical manufacturer specializing in designing and producing high-performance molecules called Supermolecules™. These molecules are created using AI-driven molecular design technology that optimizes for improved performance and seamless integration with existing industrial processes. Cambrium manufactures these novel molecules using biotechnology, enabling the creation of innovative materials that are better for people and the planet. Their business model focuses on partnering with companies to solve material challenges by delivering superior molecular solutions, with manufacturing capabilities that utilize local feedstocks close to customers. They have demonstrated successful projects including outperforming polyurethanes, creating PVC alternatives, and producing natural retinol replacements and hair bonding solutions. Cambrium is positioned as a resilient manufacturer leveraging synthetic biology, machine learning, and lab automation to accelerate biomaterial innovation at scale.
Headquarters: Berlin, Germany
Founded: 2020
Primary offering: AI-designed protein-derived performance molecules ("Supermolecules") and biomaterial manufacturing
Notable product: NovaColl (designed collagen derivative for personal care)
Approx. employees: 26
Sustainable biomaterials and advanced molecule design to replace or outperform conventional chemical and polymer solutions in personal care and materials markets.
2020
Biotechnology Research
€11 million (reported)
Reported seed raise to expand operations and structural-protein programs
$19 million (reported)
Reported Series A
“Multiple venture investors including Gradient, HOF Capital, Merantix Capital, Valor Equity Partners and others listed as participants”
| Company |
|---|